NY-GAIN-THEORY
16.1.2020 14:02:12 CET | Business Wire | Press release
Gain Theory , a WPP global marketing effectiveness consultancy that empowers marketers to create agile, smarter, data-informed cultures via data, technology and advanced analytics has been named a Strong Performer in The Forrester Wave™: Marketing Measurement and Optimization Solutions, Q1 2020. Gain Theory received the highest score possible for ten criteria including: Unified Measurement Methodology; Training and Change Management Services; Marketing Strategy Consulting; Engagement Structures; Marketing Dashboards and Reports; and Global Strategy.
The report recognizes Gain Theory’s work measuring marketing’s impact on both short and long-term business objectives and helping clients develop plans to optimize multiple objectives simultaneously. The report states: "Firms looking for more complex insights and drivers of marketing performance should put Gain Theory on their short list." Forrester notes Gain Theory’s "investments in data partnerships and machine learning to increase speed of insight." Forrester also notes Gain Theory’s deep focus on change management to help clients with the skillset development and organizational restructuring often required to activate marketing insights.
Forrester gives Gain Theory high marks for its Unified Measurement approach which "leverages a system of models that iterate and inform each other." Gain Theory’s approach is unified at three levels: data, analytics and outcomes and crafted to individual client needs. Clients note that the "sophistication" of Gain Theory’s unified model is its "main strength." Also cited is Gain Theory Sensor™ which combines individual and aggregate data to measure the value of individual campaign tactics and to conduct in-campaign tests. Sensor is a component of Gain Theory’s Unified Measurement approach but can also be used as a stand-alone solution.
"We are delighted to be recognized as a Strong Performer in Forrester’s Wave report," said Gain Theory Global CEO, Manjiry Tamhane. "It confirms for us the unique value that we deliver to our clients globally who trust us to make a meaningful difference to their business performance through our focus on improving marketing efficiency, growing market share and seeing baseline profits and share price grow. At Gain Theory we are passionate about inspiring marketing excellence and creating data-informed cultures. Championing our clients and solving their challenges is what makes our people thrive and we believe the Forrester Wave result is a testament to this."
About Gain Theory
Gain Theory is a global marketing effectiveness consultancy, empowering marketing and insight professionals to create agile, smarter , data-informed cultures using data, technology and advanced analytics .
As an independent practice within WPP , Gain Theory is trusted by clients around the world to enhance business performance in both the short and long-term by improving marketing effectiveness and efficiency, increasing baseline profits, growing market share and driving share price growth .
The global team consists of 200+ consultants, data scientists, mathematicians and marketing technology specialists who operate globally servicing 113 markets worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005055/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
